Safety and efficacy data from a Phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational next-generation CD19-directed CAR-T cell therapy produced in 48 hours using the T-CHARGE platform, shows a manageable safety profile and antitumor activity. The best overall response, defined as complete remission with complete remission or incomplete recovery of blood counts, was between 70% and 100% depending on the dose.
Please follow and like us:
